Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $14,190.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $28.38, for a total transaction of $14,190.00. Following the completion of the transaction, the director now owns 73,909 shares in the company, valued at $2,097,537.42. The trade was a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $26.61 on Friday. The firm has a 50-day simple moving average of $30.24 and a two-hundred day simple moving average of $39.32. The stock has a market cap of $1.27 billion, a PE ratio of 8.87, a P/E/G ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AMPH. GF Fund Management CO. LTD. purchased a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $38,000. Voloridge Investment Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 16.2% in the 4th quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company’s stock valued at $5,326,000 after buying an additional 19,991 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Amphastar Pharmaceuticals by 208.0% in the fourth quarter. Squarepoint Ops LLC now owns 17,664 shares of the company’s stock valued at $656,000 after acquiring an additional 11,929 shares in the last quarter. Twinbeech Capital LP purchased a new position in Amphastar Pharmaceuticals during the 4th quarter worth approximately $1,738,000. Finally, Systematic Financial Management LP acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at $9,147,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.